TY - JOUR AU - Pártos, Katalin AU - Major, Dávid AU - Dósa, Norbert Sándor AU - Fazekas-Pongor, Vince AU - Tabák, Ádám AU - Ungvári, Zoltán AU - Horváth, Ildikó AU - Barta, Ildikó AU - Pozsgai, Éva AU - Bodnár, Tamás AU - Fehér, Gergely AU - Lenkey, Zsófia AU - Fekete, Mónika AU - Springó, Zsolt TI - Diagnosis rates, therapeutic characteristics, lifestyle, and cancer screening habits of patients with diabetes mellitus in a highly deprived region in Hungary: a cross-sectional analysis JF - FRONTIERS IN ENDOCRINOLOGY J2 - FRONT ENDOCRINOL VL - 15 PY - 2024 SN - 1664-2392 DO - 10.3389/fendo.2024.1299148 UR - https://m2.mtmt.hu/api/publication/34830215 ID - 34830215 LA - English DB - MTMT ER - TY - JOUR AU - Gadó, Klára AU - Tabák, Ádám AU - Vingender, István AU - Domján, Gyula AU - Bednárikné Dörnyei, Gabriella TI - Treatment of type 2 diabetes mellitus in the elderly – Special considerations JF - PHYSIOLOGY INTERNATIONAL J2 - PHYSIOL INT VL - in press PY - 2024 IS - in press PG - 22 SN - 2498-602X DO - 10.1556/2060.2024.00317 UR - https://m2.mtmt.hu/api/publication/34826851 ID - 34826851 AB - Type 2 diabetes is a frequent chronic disease. Given its strong positive association with older age, it is a significant public health issue in elderly populations. Furthermore, the aging of the population, driven by increasing life expectancy in high and middle-income countries leads to an increasing prevalence of diabetes. LA - English DB - MTMT ER - TY - CHAP AU - Tabák, Ádám ED - Takács, István TI - Hypoglykaemiák T2 - Belgyógyászat 1 tantárgyi jegyzet PB - Semmelweis Kiadó CY - Budapest SN - 9789633316122 PY - 2024 SP - 145 EP - 147 PG - 3 UR - https://m2.mtmt.hu/api/publication/34804963 ID - 34804963 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Tabák, Ádám ED - Takács, István TI - Ketoacidosis, hyperosmolaris coma T2 - Belgyógyászat 1 tantárgyi jegyzet PB - Semmelweis Kiadó CY - Budapest SN - 9789633316122 PY - 2024 SP - 142 EP - 145 PG - 4 UR - https://m2.mtmt.hu/api/publication/34804957 ID - 34804957 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Ferencz, Viktória AU - Tabák, Ádám ED - Takács, István TI - Nephropathia diabetica T2 - Belgyógyászat 1 tantárgyi jegyzet PB - Semmelweis Kiadó CY - Budapest SN - 9789633316122 PY - 2024 SP - 139 EP - 139 PG - 1 UR - https://m2.mtmt.hu/api/publication/34804467 ID - 34804467 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Zsirai, László AU - Kun, Attila AU - Visolyi, Gergely AU - Svébis, Márk Márton AU - Domján, Beatrix Annamária AU - Tabák, Ádám TI - Birthweight trends and their explanatory factors in Hungary between 1999 and 2018. an analysis of the Hungarian Tauffer registry TS - an analysis of the Hungarian Tauffer registry JF - REPRODUCTIVE HEALTH J2 - REPROD HEALTH VL - 21 PY - 2024 IS - 1 PG - 13 SN - 1742-4755 DO - 10.1186/s12978-024-01787-0 UR - https://m2.mtmt.hu/api/publication/34797483 ID - 34797483 N1 - Funding Agency and Grant Number: Semmelweis University; UK Medical Research Council [S011676]; Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund (2021 Thematic Excellence Programme funding scheme) [TKP2021-NKTA-47] Funding text: This study has not received any specific funding. Open access funding was provided by Semmelweis University. Prof Tabak is supported by the UK Medical Research Council (S011676) and the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund (2021 Thematic Excellence Programme funding scheme, TKP2021-NKTA-47).The sponsors had no role in study design, in the collection, analysis and inter-pretation of data, in the writing of the report, and in the decision to submit the article for publication AB - The increasing birthweight trend stopped and even reversed in several high income countries in the last 20 years, however the reason for these changes is not well characterized. We aimed to describe birthweight trends of term deliveries in Hungary between 1999 and 2018 and to investigate potential maternal and foetal variables that could drive these changes.We analysed data from the Hungarian Tauffer registry, a compulsory anonymized data collection of each delivery. We included all singleton term deliveries in 1999-2018 (n = 1,591,932). We modelled birthweight trends separately in 1999-2008 and 2008-2018 in hierarchical multiple linear regression models adjusted for calendar year, newborn sex, maternal age, gestational age at delivery, and other important determinants.Median birthweights increased from 3250/3400 g (girl/boy) to 3300/3440 g from 1999 to 2008 and decreased to 3260/3400 g in 2018. When we adjusted for gestational age at delivery the increase in the first period became more pronounced (5.4 g/year). During the second period, similar adjustment substantially decreased the rate of decline from 2.5 to 1.4 g/year. Further adjustment for maternal age halved the rate of increase to 2.4 g/year in the first period. During the second period, adjustment for maternal age had little effect on the estimate.Our findings of an increasing birthweight trend (mostly related to the aging of the mothers) in 1999-2008 may forecast an increased risk of cardiometabolic diseases in offsprings born in this period. In contrast, the decreasing birthweight trends after 2008 may reflect some beneficial effects on perinatal morbidity. However, the long-term effect cannot be predicted, as the trend is mostly explained by the shorter pregnancies. LA - English DB - MTMT ER - TY - JOUR AU - Tabák, Ádám AU - Kempler, Péter AU - Guja, Cristian AU - Eldor, Roy AU - Haluzik, Martin AU - Klupa, Tomasz AU - Papanas, Nikolaos AU - Stoian, Anca Pantea AU - Mankovsky, Boris TI - Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel. JF - DIABETES THERAPY J2 - DIABTHERAP VL - In press PY - 2024 SP - In press SN - 1869-6953 DO - 10.1007/s13300-024-01556-z UR - https://m2.mtmt.hu/api/publication/34741829 ID - 34741829 N1 - Journal Article; Review AB - Despite the availability of various antihyperglycaemic therapies and comprehensive guidelines, glycaemic control in diabetes management has not improved significantly during the last decade in the real-world clinical setting. Treatment inertia arising from a complex interplay among patient-, clinician- and healthcare-system-related factors is the prime reason for this suboptimal glycaemic control. Also, the key factor leading to inadequate glycaemic levels remains limited communication between healthcare professionals (HCPs) and people with type 2 diabetes (PwT2D). Early insulin administration has several advantages including reduced glucotoxicity, high efficacy and preserved β-cell mass/function, leading to lowering the risk of diabetes complications. The current publication is based on consensus of experts from the South-Eastern European region and Israel who reviewed the existing evidence and guidelines for the treatment of PwT2D. Herein, the experts emphasised the timely use of insulin, preferably second-generation basal insulin (BI) analogues and intensification using basal-plus therapy, as the most-potent glucose-lowering treatment choice in the real-world clinical setting. Despite an increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the experts urged timely insulin initiation for inadequate glycaemic control in PwT2D. Furthermore, the combination of BI and GLP-1 RA addressing both fasting plasma glucose and post-prandial excursions as a free- or fixed-ratio combination was identified to reduce treatment complexity and burden. To minimise discontinuation and improve adherence, the experts reiterated quality, regular interactions and discussions between HCPs and PwT2D/carers for their involvement in the diabetes management decision-making process. Clinicians and HCPs should consider the opinions of the experts in accordance with the most recent recommendations for diabetes management. LA - English DB - MTMT ER - TY - JOUR AU - Ungvári, Zoltán István AU - Tabák, Ádám AU - Ádány, Róza AU - Purebl, György AU - Kaposvári, Csilla AU - Fazekas-Pongor, Vince AU - Csípő, Tamás AU - Szarvas, Zsófia AU - Horváth, Krisztián AU - Mukli, Péter AU - Balog, Piroska AU - Bódizs, Róbert AU - Ujma, Przemyslaw Péter AU - Stauder, Adrienne AU - Belsky, Daniel W. AU - Kovács, Illés AU - Yabluchanskiy, Andriy AU - Maier, Andrea B. AU - Moizs, Mariann AU - Östlin, Piroska AU - Yon, Yongjie AU - Varga, Péter AU - Vokó, Zoltán AU - Papp, Magor Csongor AU - Takács, István AU - Vásárhelyi, Barna AU - Torzsa, Péter AU - Ferdinandy, Péter AU - Csiszar, Anna AU - Benyó, Zoltán AU - Szabó, Attila AU - Bednárikné Dörnyei, Gabriella AU - Kivimäki, Mika AU - Kellermayer, Miklós AU - Merkely, Béla Péter TI - The Semmelweis Study: a longitudinal occupational cohort study within the framework of the Semmelweis Caring University Model Program for supporting healthy aging JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - 46 PY - 2024 IS - 1 SP - 191 EP - 218 PG - 28 SN - 2509-2715 DO - 10.1007/s11357-023-01018-7 UR - https://m2.mtmt.hu/api/publication/34425939 ID - 34425939 N1 - International Training Program in Geroscience/Healthy Aging Program, Doctoral School of Basic and Translational Medicine/Department of Public Health, Semmelweis University, Budapest, Hungary Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States Department of Health Promotion Sciences, The Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States Department of Public Health, Faculty of Medicine, Semmelweis University, Budapest, Hungary UCL Brain Sciences, University College London, London, United Kingdom Department of Internal Medicine and Oncology, Semmelweis University, Faculty of Medicine, Budapest, Hungary HUN-REN-UD Public Health Research Group, Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Institute of Behavioral Sciences, Faculty of Medicine, Semmelweis University, Budapest, Hungary Robert N. Butler Columbia Aging Center, Columbia University, New York, NY, United States Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States Department of Ophthalmology, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Ophthalmology, Weill Cornell Medical College, New York City, NY, United States Department of Clinical Ophthalmology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore Centre for Healthy Longevity, National University Health System, Singapore, Singapore Department of Human Movement Sciences, @AgeAmsterdam, Vrije Universiteit, Amsterdam Movement Sciences, Amsterdam, Netherlands Ministry of Interior of Hungary, Budapest, Hungary WHO Regional Office for Europe, Copenhagen, Denmark Clinical Center, Semmelweis University, Budapest, Hungary Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary Department of Laboratory Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Family Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary Department of Translational Medicine, Faculty of Medicine, Semmelweis University, Budapest, Hungary HUN-REN-SU Cerebrovascular and Neurocognitive Diseases Research Group, Budapest, Hungary First Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary HUN-REN-SU Pediatrics and Nephrology Research Group, Semmelweis University, Budapest, Hungary Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, Budapest, Hungary Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary Heart and Vascular Center, Semmelweis University, Budapest, Hungary Cited By :1 Export Date: 29 February 2024 Correspondence Address: Ungvari, Z.; International Training Program in Geroscience/Healthy Aging Program, Hungary; email: Zoltan-Ungvari@ouhsc.edu Correspondence Address: Adany, R.; International Training Program in Geroscience/Healthy Aging Program, Hungary AB - The Semmelweis Study is a prospective occupational cohort study that seeks to enroll all employees of Semmelweis University (Budapest, Hungary) aged 25 years and older, with a population of 8866 people, 70.5% of whom are women. The study builds on the successful experiences of the Whitehall II study and aims to investigate the complex relationships between lifestyle, environmental, and occupational risk factors, and the development and progression of chronic age-associated diseases. An important goal of the Semmelweis Study is to identify groups of people who are aging unsuccessfully and therefore have an increased risk of developing age-associated diseases. To achieve this, the study takes a multidisciplinary approach, collecting economic, social, psychological, cognitive, health, and biological data. The Semmelweis Study comprises a baseline data collection with open healthcare data linkage, followed by repeated data collection waves every 5 years. Data are collected through computer-assisted self-completed questionnaires, followed by a physical health examination, physiological measurements, and the assessment of biomarkers. This article provides a comprehensive overview of the Semmelweis Study, including its origin, context, objectives, design, relevance, and expected contributions. LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Viktor József AU - Békeffy, Magdolna Zsófia AU - Németh, Zsuzsanna AU - Szelke, Emese AU - Fazekas-Pongor, Vince AU - Hajdú, Noémi AU - Svébis, Márk Márton AU - Pintér, József AU - Domján, Beatrix Annamária AU - Mészáros, Szilvia AU - Körei, Anna Erzsébet AU - Kézdi, Árpád AU - Kocsis, Ibolya AU - Kristóf, Katalin AU - Kempler, Péter AU - Rozgonyi, Ferenc AU - Takács, István AU - Tabák, Ádám TI - The effect of COVID-19 vaccination status on all-cause mortality in patients hospitalised with COVID-19 in Hungary during the delta wave of the pandemic JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - 46 PY - 2024 IS - 2 SP - 1881 EP - 1894 PG - 14 SN - 2509-2715 DO - 10.1007/s11357-023-00931-1 UR - https://m2.mtmt.hu/api/publication/34163215 ID - 34163215 N1 - Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, 2/a Korányi S. Str, Budapest, 1083, Hungary Department of Public Health, Semmelweis University Faculty of Medicine, Budapest, Hungary Department of Laboratory Medicine, Semmelweis University Faculty of Medicine, Budapest, Hungary UCL Brain Sciences, University College London, London, United Kingdom Export Date: 6 April 2024 Correspondence Address: Horvath, V.J.; Department of Internal Medicine and Oncology, 2/a Korányi S. Str, Hungary; email: horvathjviktor@gmail.com Chemicals/CAS: C reactive protein, 9007-41-4; colecalciferol, 1406-16-2, 67-97-0; dexamethasone, 50-02-2; elasomeran, 2430046-03-8, 2457298-05-2; ibacovavec, 2541607-46-7; procalcitonin, 56645-65-9; serum albumin, 9048-46-8; tozinameran, 2417899-77-3; vaxzevria, 2420395-83-9; COVID-19 Vaccines Tradenames: bbibp corv, Sinopharm; comirnaty, BioNTech; gam covid vac, Gamaleya; jcovden, Jansen; spikevax, Moderna; vaxzevria, Astra ZenecaIBM SPSS Statistics for Windows Version 28.0.1.0, IBM, United States Manufacturers: Astra Zeneca; BioNTech; Gamaleya; Jansen; Moderna; Pfizer; SinopharmIBM, United States Funding details: Medical Research Council, MRC, S011676 Funding details: Semmelweis Egyetem Funding details: NordForsk, 75021 Funding details: Nemzeti Kutatási, Fejlesztési és Innovaciós Alap, NKFIA, TKP2021-NKTA-47 Funding text 1: Open access funding provided by Semmelweis University. Dr Tabák is supported by the UK Medical Research Council (S011676), the NordForsk (the Nordic Research Programme on Health and Welfare, 75021), and the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund (2021 Thematic Excellence Programme funding scheme, TKP2021-NKTA-47). AB - The high mortality of patients with coronavirus disease 2019 (COVID-19) is effectively reduced by vaccination. However, the effect of vaccination on mortality among hospitalised patients is under-researched. Thus, we investigated the effect of a full primary or an additional booster vaccination on in-hospital mortality among patients hospitalised with COVID-19 during the delta wave of the pandemic. This retrospective cohort included all patients (n = 430) admitted with COVID-19 at Semmelweis University Department of Medicine and Oncology in 01/OCT/2021–15/DEC/2021. Logistic regression models were built with COVID-19-associated in-hospital/30 day-mortality as outcome with hierarchical entry of predictors of vaccination, vaccination status, measures of disease severity, and chronic comorbidities. Deceased COVID-19 patients were older and presented more frequently with cardiac complications, chronic kidney disease, and active malignancy, as well as higher levels of inflammatory markers, serum creatinine, and lower albumin compared to surviving patients (all p < 0.05). However, the rates of vaccination were similar (52–55%) in both groups. Based on the fully adjusted model, there was a linear decrease of mortality from no/incomplete vaccination (ref) through full primary (OR 0.69, 95% CI: 0.39–1.23) to booster vaccination (OR 0.31, 95% CI 0.13–0.72, p = 0.006). Although unadjusted mortality was similar among vaccinated and unvaccinated patients, this was explained by differences in comorbidities and disease severity. In adjusted models, a full primary and especially a booster vaccination improved survival of patients hospitalised with COVID-19 during the delta wave of the pandemic. Our findings may improve the quality of patient provider discussions at the time of admission. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Gábor AU - Mohos, Elemér AU - Kis, János Tibor AU - Tabák, Ádám AU - Gerendy, Péter AU - Pettkó, Judit AU - Nagy, Dávid AU - Győrbíró, Dávid AU - Kaló, Zoltán TI - Cost-Effectiveness of Bariatric Surgery in Patients Living with Obesity and Type 2 Diabetes JF - JOURNAL OF DIABETES RESEARCH J2 - J DIABETES RES VL - 2023 PY - 2023 PG - 8 SN - 2314-6745 DO - 10.1155/2023/9686729 UR - https://m2.mtmt.hu/api/publication/34440559 ID - 34440559 AB - Aims. The favourable effects of bariatric surgeries on body weight reduction and glucose control have been demonstrated in several studies. Additionally, the cost-effectiveness of bariatric surgeries has been confirmed in several analyses. The aim of the current analysis was to demonstrate the cost-effectiveness of bariatric surgeries in obese patients with type 2 diabetes in Hungary compared to conventional diabetes treatments based on economic modelling of published clinical trial results. Materials and Methods. Patients entered the simulation model at the age of 45 with kg/m2 and type 2 diabetes. The model was performed from the public payer’s perspective, comparing sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) procedures to conventional care of diabetes. The results were provided separately for three BMI categories. Results. The base-case analysis demonstrated that both surgery types were dominant; i.e., they saved 17 064 to 24 384 Euro public payer expenditures and resulted in improved health outcomes (1.36 to 1.50 quality-adjusted life years gain (QALY)) in the three BMI categories. Bariatric surgeries extended the life expectancy and the disease-free survival times of all the investigated diabetes complications. All the scenario analyses confirmed the robustness of the base-case analysis, such that bariatric surgeries remained dominant compared to conventional diabetes treatments. Conclusion. The results of this cost-effectiveness analysis highlight the importance of bariatric surgeries as alternatives to conventional diabetes treatments in the obese population. Therefore, it is strongly recommended that a wider population has access to these surgeries in Hungary. LA - English DB - MTMT ER -